Nicotinamide mononucleotide (NMN) has become one of the most talked-about longevity supplements, usually in the context of NAD+ levels, energy and healthy aging. A new systematic review and meta-analysis in Nutrients (Zhang et al., 2026) asks a more practical question: does it move blood pressure in people whose readings are already elevated? The answer is a cautious maybe, with the biggest signal showing up in adults aged 60 and older.
What the Researchers Did
The team searched PubMed/MEDLINE, Scopus, Web of Science and EBSCO from their inception through 13 December 2025 for randomized controlled trials of NMN supplementation that reported resting blood pressure. They pooled the data from 10 RCTs, covering 11 intervention arms and 349 participants, and compared NMN with placebo.
They combined results using a common-effects model in R. They then ran subgroup analyses by age, baseline body mass index, geographic location, intervention duration, NMN dosage and baseline blood pressure.
The Headline Numbers
- Diastolic blood pressure (DBP): NMN was associated with a statistically significant but modest reduction of -2.15 mmHg (95% CI: -3.68 to -0.61) versus placebo.
- Systolic blood pressure (SBP): The overall reduction was not statistically significant.
- Adults 60 and older: In the age subgroup analysis, SBP fell by -3.94 mmHg (95% CI: -7.06 to -0.82).
The over-60 finding is the most eye-catching result, but it deserves careful reading. The confidence interval is wide, running from a drop of about 7 mmHg to less than 1 mmHg. That range spans everything from a clinically interesting effect to a negligible one.
Putting a 2 to 4 mmHg Drop in Context
A reduction of roughly 2 mmHg in diastolic pressure is real in a statistical sense, but small in everyday terms. For comparison, standard antihypertensive medications typically lower systolic pressure by considerably more, and lifestyle changes such as cutting sodium, losing weight and exercising regularly can produce comparable or larger shifts. Population-level models do suggest that even small average reductions can matter across large groups of people over many years, but that is not the same as showing that one person taking NMN will see a meaningful health benefit.
The authors themselves describe their findings as "preliminary and suggestive." NMN is not shown here to be a substitute for blood pressure medication, and nothing in this analysis supports stopping or reducing prescribed treatment.
Why the Over-60 Signal Is Interesting but Fragile
There is a plausible biological story. NAD+ levels tend to decline with age, and NAD+ is involved in vascular function, mitochondrial health and cellular stress responses. If NMN raises NAD+ availability, older adults, who may start from a lower baseline and often have stiffer arteries, might be more responsive. That is a reasonable hypothesis, but this analysis cannot confirm the mechanism.
Several cautions apply:
- Small total sample. With 349 participants spread across 10 trials, each subgroup is smaller still. Subgroup findings are more prone to chance results.
- Subgroup analysis. The overall SBP effect was not significant. Finding a significant result in one slice of the data is a hypothesis to test, not a conclusion.
- Common-effects model. This approach assumes that all trials are estimating one single true effect. If the studies differ in dose, duration, population and formulation, as they often do, a random-effects model would typically give wider intervals and more conservative results. Readers should treat the precision as potentially optimistic.
- Heterogeneous interventions. The trials used various NMN regimens, so a single pooled number blurs differences between them.
Doses and Duration
The abstract states that subgroup analyses were carried out by NMN dosage and intervention duration, but it does not report the specific doses or treatment lengths used. Based on the source material, the safest statement is that doses and durations varied across trials. Anyone interested in specifics should consult the full paper rather than extrapolating a dose from this summary.
Who Might Care About This
The analysis focused on adults with elevated blood pressure, so the findings are most relevant to:
- Older adults, particularly those 60+, who are already exploring NMN for healthy aging
- People with mildly raised readings who are looking for adjuncts to lifestyle changes, under medical guidance
- Researchers designing larger trials of NAD+ precursors
It is less relevant to people with normal blood pressure, and it is not evidence for treating hypertension with NMN alone.
What We Still Don't Know
The authors call for long-term, large-scale, high-quality RCTs. Open questions include whether the effect persists beyond the short durations typical of supplement trials, whether it translates into fewer cardiovascular events, how NMN compares with other NAD+ precursors such as nicotinamide riboside, and which patients are most likely to respond. Home or 24-hour ambulatory blood pressure measurements in future trials would also help separate real effects from clinic-visit noise.
Practical Takeaways
- The effect is modest. About -2.15 mmHg for diastolic pressure is statistically significant but small.
- Overall systolic pressure did not change significantly. The -3.94 mmHg systolic drop appeared only in the 60+ subgroup.
- Evidence is early. Ten trials and 349 people is a limited foundation, and the authors label the results preliminary.
- NMN is not a blood pressure drug. Do not replace or reduce prescribed medication on the basis of this analysis.
- Talk to your doctor first. This matters especially if you take antihypertensives, have kidney or heart conditions, or are pregnant or breastfeeding. Monitor your blood pressure at home if you start any new supplement.
- Fundamentals still win. Diet, activity, sleep, weight management and sodium reduction have stronger evidence for lowering blood pressure.
Bottom Line
This meta-analysis adds a useful, if tentative, data point to the NMN conversation. It suggests a small diastolic benefit and a possible systolic benefit in older adults, but the sample is small, the model is optimistic and the key finding comes from a subgroup. For now, NMN looks like an interesting candidate worth testing properly, not an established tool for managing blood pressure.
